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Abstract 
Introduction 
Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic 
pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure.  
Areas covered 
The present review assesses the principal pharmacological strategies that have been tested for an HIV cure 
starting from the in vitro proof of concept and the potential rationale of their in vivo applicability. We 
evaluated the possible pharmacological procedures employed during the early-stage HIV infection and the 
possibility of cART-free remission. We then analysed the shock and kill approach from the single 
compounds in vitro mechanism of action, to the in vivo application of single or combined actions. Finally, 
we briefly considered the novel immunological branch through the discovery and development of broadly 
neutralizing antibodies in regard of the current and future in vivo therapeutic strategies aiming to verify the 
clinical applicability of these compounds. 
Expert opinion  
Despite an incredible effort in HIV research cure, the likelihood of completely eradicating HIV is 
unreachable within our current knowledge. A better understanding of the mechanism of viral latency and 
the fully characterization of HIV reservoir are crucial for the discovery of new therapeutic targets and novel 
pharmacological entities. 
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1.0 Introduction 
Combined antiretroviral therapy (cART), with the introduction of protease inhibitors in middle 90’, has led 
to a dramatic change in the life expectancy of HIV infected patients by transforming an inexorably 
progressive disease into a chronic one. cART is able to control the human immunodeficiency virus type-
1(HIV)’s replication by interfering with different steps of the HIV life cycle, including cell entry, reverse 
transcription, integration, and assembling of the virion. Several problems are still present in the treatment 
of HIV infection and in particular if on the one-hand cART is able to inhibit  the virus replication  reaching 
undetectable levels of HIV-RNA in plasma, on the other the persistence of the virus in the so-called 
reservoir prevents the possibility of its eradication [1]. The HIV reservoir is composed by quiescent cells 
that can undergo clonal expansion and either maintain or increase the size of the reservoir without 
producing life-long persisting virus. Moreover, the quantification of the reservoir and the measurement of 
its size are still subject of debate and different techniques to quantify HIV reservoir are applied in different 
studies [2]. At the moment, no standardized assay is available to assess the magnitude of viral reservoir and 
this limits the comparability of different studies. For example, PCR based methods are likely to 
overestimate the size of viral reservoir whereas culture-based methods are likely to underestimate it, 
leading to potential misclassification of patients as cured or not. Thus, the real efficacy of HIV eradication 
strategies is actually hardly to account [2]. One of the major challenges with which scientist has to face up 
is the difficulty in the identification of specific markers able to specifically target the cells which composed 
the HIV reservoir. Descours B et al suggested that CD32a+ cells could play an important role as HIV reservoir 
because those cells were highly enriched in inducible replication-competent proviruses. These authors 
suggested that CD32a+ lymphocytes, representing the elusive HIV-1 reservoir, may lead to insights that will 
facilitate the specific targeting and eventually its elimination [3]. Unfortunately, these findings have been 
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reconsidered according to the work of Abdel-Mohsen et al. that examined T cells from treated HIV patients. 
They found that CD32+ HIV-infected T cells had an activated phenotype and HIV RNA, indicating active HIV 
transcription. In contrast, the majority of HIV DNA resided in CD32− cells. Their results suggest that 
targeting CD32+ cells is unlikely to hit the HIV latent reservoir [4]. Moreover, a recent work by Bertagnolli et 
al showed how there is no evidence that CD32 expression indicates the presence of latent HIV-1, and found 
that a not negligible fraction of the HIV latent reservoir is in CD3+CD4+CD32− T cells. Moreover, the authors 
suggested that the findings by Descours et al could be driven by the use of an ultrasensitive p24 ELISA assay 
that may account for the apparent enrichment observed in culture experiments [5]. Indeed, if cART is 
interrupted, the HIV production by these cells is observed within 2 to 4 weeks. Thus, in the absence of 
cART, cells that harbour quiescent replication-competent virus can rekindle HIV replication and 
transmission [1]. Recently an alternative and broader definition of viral reservoir has been suggested: all 
infected cells containing all forms of HIV persistence that can participate in HIV pathogenesis [6]. This 
broader definition includes defective proviruses that could theoretically play a role in HIV pathogenesis 
through the production of viral proteins and the subsequent induction of chronic immune activation [7]. In 
other words, proviruses that are not fully replication-competent, but that are capable of transcribing viral 
mRNAs and/or translating viral proteins, may constitute an additional dimension to persistence studies [8]. 
Moreover, a chronic state of immune activation combined with a persistent pro-inflammatory state leads 
to a premature aging and to an increased frequency of non-AIDS related illness [9]. In the context of a 
possible virological control with a deferred progression of HIV infection due to cART, the focus in HIV 
research is now posed on the possibility of HIV control in the absence of cART and, in the end, on the 
possibility of HIV complete eradication from the body.  The greatest challenge in the prospect to achieve a 
cure of HIV infection is to eliminate all replication-competent virus in the reservoir or, if this could not be 
achieved, to obtain a lifelong remission without the use of cART. Several strategies have been addressed 
both in animals and human models but nowadays all have failed to achieve HIV cure [10]. In fact, the only 
patient who have been cured from HIV infection was the so-called “Berlin patient”. Timothy Brown 
received a hematopoietic stem cell transplant from a donor whose cells were resistant to HIV infection due 
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to the delta32 mutation in the HIV coreceptor CC chemokine receptor 5 (CCR5). Mr. Brown, who has not 
been receiving cART for more than 10 years, has no evidence of replication-competent HIV [11]. Although 
the transplantation approach is intriguing, it has to be considered just a proof of concept for possible future 
eradication strategies due to the high mortality risk for the patient and also to the large cost.  
In this review we are going to examine all the possible pharmacological approaches that have been tested, 
the one which still are ongoing in trial and also the future perspectives regarding HIV cure.  
2.0 Very early treatment and ART free remission 
Several studies have assessed the possibility of reducing the viral reservoir and consequently to pose the 
foundation for a possible HIV cure by using cART in the early phase of infection. These studies start from 
the observation that HIV reservoir begins to increase dramatically as soon as HIV-RNA becomes detectable 
in plasma and it persists to increase in the following weeks [12]. One of the strategies tested was treatment 
intensification during the early stage of HIV infection: the addition of maraviroc to a cART regimen results in 
faster reduction of 2-long terminal repeat (LTR) newly infected cells and recovery of CD4 T-cell counts, and 
a modest reduction in total reservoir size after 48 weeks of treatment. However, CCR5 blockade also 
induced a slower decrease in plasma viremia and immune activation [13]. As shown by Crowell and 
colleagues, the presence of detectable colonic HIV RNA at the time of cART initiation during acute HIV 
infection, resulted associated with higher levels of proviral DNA suggesting that the seeding of HIV in the 
gut may have long-lasting effects on the size of persistent viral reservoirs and may represent an important 
therapeutic target in eradication strategies [14]. Due to its rapid infiltration by HIV during the early phase of 
infection, the colon may be a target to reduce the rapid instauration of the reservoir. A possible 
intervention designed to prevent colonic infiltration could be the use of anti-α4β7 monoclonal antibody 
administration, to block the interaction between the HIV envelope and gut-homing integrins. This kind of 
intervention has to be conducted before peripheral blood HIV RNA reaches peak levels. In animal model, 
anti-α4β7 has been able to prevent mucosal infection by simian immunodeficiency virus and in the early 
phase of infection it is able to protect both blood and gut-associated lymphoid tissue CD4 T cells from 
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infection [15]. Another potential intervention tested during SIV acute infection in rhesus macaques is the 
caspase inhibitor Q-VD-OPH which demonstrated first of all to reduce T cell death, secondly to preserve of 
CD4+/CD8+ T cell ratio in lymphoid organs and in the gut and also to maintain memory CD4+ T cells with 
increased specific CD4+ T cell response with the production of cytotoxic molecules [16].  If it is true that 
very early cART start, within 2 weeks from HIV infection, could significantly reduce the size of viral 
reservoir, making almost impossible its quantification, unfortunately, it does not correspond to a significant 
clinical improvement for the patient [17]. In fact, infection rebounds when treatment is interrupted by 
reactivation of virus production from this reservoir [18]. This finding was also confirmed in subjects treated 
in an extremely early phase of HIV infection, i.e. Fieibig I stage, leading to an almost complete 
undetectability of HIV-DNA in blood and tissue sampled. However, it is possible that the very small size of 
the latently infected cells could lead to a delayed rebound of HIV viremia [19, 20]. Lymphoid tissues are the 
principal sites of production and persistence before initiating cART and if cART is interrupted a rebound of 
the plasmatic HIV-RNA is observed shortly thereafter. One possible explanation about the persistent 
replication of HIV at tissue level, albeit an undetectable HIV-RNA in plasma, could be a low penetration of 
antiretrovirals in lymphoid tissues despite therapeutic concentrations obtained in blood [21]. Sequence 
analysis revealed a great number of rebounding viruses representing recrudescent viremia from multiple 
sources. These findings suggest that the HIV reactivation arises from many latently infected cells at multiple 
sites. Unfortunately, the large pool of cells and sites that are able to rekindle recrudescent infection 
highlights the challenges in eradicating HIV [22].  The first data showing a possible role in HIV “functional” 
cure of early antiretroviral treatment came from the VISCONTI study in which 14 patients, who initiated 
cART within 3 months of their estimated date of infection, remained on durable treatment for 1–8 years 
controlling HIV replication after cART interruption [23, 24]. The so-called “post-treatment controllers” have 
maintained their plasma HIV RNA levels to <50 copies per mL, with the exception of a few viral blips with a 
good median CD4 cell count after cART interruption. Apart from the VISCONTI cohort, amid patients there 
have also been other anecdotal reports of post treatment controllers [25]. The patient’s subsets with 
primary HIV infection are the ideal candidates for intervention strategies with therapeutic vaccines. Such  
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interventions could lead to an interruption of cART with a control of HIV replication hopefully through the 
employment of a “functional cure” ,since unfortunately  they cannot cause an HIV eradication [26]. The 
eradication strategy of a very early cART treatment has not worked even in children, who are in many ways 
the best population to apply it [27, 28]. To achieve sustained virological control of HIV-1, without the need 
of continuous cART, and to clear virus-expressing cells, it is likely that immune-based therapies will be 
needed, nevertheless therapeutic HIV vaccine trials in chronic HIV infection have obtained very few clinical 
benefits. The subset of subjects with a primary HIV infection is a specific target population allowing to study 
the role of HIV therapeutic vaccines in individuals who have experienced an early cART start. It was 
observed that this approach has led to few or no viral escape, less CD4 depletion and more preserved 
memory T cells. 
In conclusion if on the one hand it is unlikely that future improvement in cART strategies could led to a 
potential HIV “functional” cure on the other hand more studies are required for the characterization of 
immune responses following treatment initiation at different stages of primary HIV infection, since 
responses to therapeutic vaccines may vary depending on the pre-existing HIV-specific immune responses 
[26]. 
3.0 Shock and Kill strategies 
The most explored strategy in tackling HIV-1 reservoirs — “shock and kill” — describes the broadly explored 
pharmacological way of kicking the latent provirus, with subsequent killing of the virus-producing cells by 
the immune system [29]. One strategy to eliminate latency is to activate virus production using latency 
reversing agents (LRAs) with the goal of triggering cell death through virus-induced cytolysis or immune-
mediated clearance. However, multiple studies have demonstrated that activation of viral transcription 
alone is insufficient to induce cell death and some LRAs may counteract cell death by promoting cell 
survival. Some have advocated approaches that activate latent reservoir cells, thereby allowing them to be 
destroyed. Clinical trials of such latency-reversing classes of drugs like histone deacetylase inhibitors 
(HDACi) suggest that they can induce some expression of latent HIV although not its clearance [30]. Other 
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drug classes, such as activators of protein kinase C or toll-like receptors, may be more effective [31]. Given 
potentially large HIV reservoirs , the extent to which these agents could provide adequate awakening of 
latent virus is unclear [32]. Their potential role should not just be considered alone but combined together 
with an immune-based therapy to kill the re-activated cells.  
2.2.2 The “shock” 
LRAs which are currently being investigated, include HDACi inhibitors, toll-like receptor agonists, activators 
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB), disulfiram, immune checkpoint 
inhibitors, and agents that affect the STAT5 signaling pathway and mTOR signalling (Table 1) (Figure 1). 
However, studies to date indicate that, compared with maximal T-cell activation, few LRAs worked 
effectively well ex vivo with cells from HIV-infected patients. It has been well recognized that epigenetic 
regulation of histone tails at the HIV LTR is critical for the establishment of latent reservoirs. Recent studies 
showed that HDACi or histone methyltransferase can reactivate HIV and some of these inhibitors have been 
investigated as LRAs in human clinical trials (Table 2)[33]. First of all, it is worth mentioning the valproic 
acid, a well-known drug used commonly against seizures or migraine, which emerged as a potential LRA 
thank to a study supervised by Margolis and published on Lancet in 2005. This work gained such huge 
resonance because scientists noticed that three out of four patients, under a HAART regimen and 
successfully suppressed, underwent a significant decrease in the frequency of latently infected CD4+ T-cells 
when enfuvirtide and valproic acid were added for 12 weeks [34]. Although this work presented many weak 
points such as the fact that it was not controlled, the impossibility to quantify the effect of the single drug, 
or again that the number of CD4+ T cell is significantly fluctuant even in stable patients , it raised great 
enthusiasm about the subject [35]. However successive research failed to confirm such promising results, 
defining the usefulness of valproic acid addition of limited value [36- 38]. Next, vorinostat administration 
has led to an increase in cell-associated HIV RNA within circulating resting cd4+ t cells in patients under 
cART [30, 39]. However, there is not an agreement about the dose regimen to apply in order to obtain a 
complete depletion of the reservoirs [40, 41]. Another potent member of these series is panobinostat, 
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which demonstrated to be able to reverse latency with a high level both of cell-associated unspliced HIV 
RNA and plasma viremia  other than to increase the amount of sytemic histone acetilation both in vitro and 
in BLT (bone marrow, liver, thymus) mice [42, 43]. Despite these promising results, panobinostat has not 
proved to obtain a drop in the levels of latent-infected CD4+ T cells suggesting that a combination therapy 
may be necessary [42, 43]. Finally, romidespin has to be mentioned within the HADC pool of compounds. It 
has shown to be able to induce HIV expression ex vivo at concentrations that can be achieved clinically, 
indicating that the drug may reactivate latent HIV in patients on suppressive cART and also resulted much 
more potent than its above-mentioned counterparts [44]. Romidepsin has also displayed significant viral 
reactivation in vivo in long-term suppressed HIV-1 individuals on antiretroviral therapy after different cycles 
of infusions. In fact, Søgaard et al. observed clear increases in lymphocyte H3 acetylation, HIV-1 
transcription, and plasma HIV-1 RNA. Importantly, this reversal of HIV-1 latency could be measured using 
standard clinical assays for detection of plasma HIV-1 RNA. Furthermore, romidepsin did not alter the 
proportion of HIV-specific T cells nor inhibit T cell cytokine production which is critically important for 
future trials combining HDACi with interventions [45]. Interestingly, a work by Winckelmann et al. shed 
light on the source of the romidespin-induced viremia. They found out that, in spite of the intermingling of 
the cell-associated HIV-1 RNA with DNA sequences indicates transcription from a diverse range of 
proviruses, the expansions of identical viral plasma sequences with few defects show that the romidepsin-
induced viremia arises from intact proviruses with highly similar or identical genetic backgrounds. This 
evidence may suggest that a specific subset of transcriptionally activated proviruses contributed to the 
majority of viremia [46]. 
Several bromodomain inhibitors have been investigated in vitro as possible compounds able to reactivate 
HIV-1 latent proviruses [47]. Bromodomain and extraterminal (BET) protein family is a highly-conserved 
class of transcriptional regulators that are characterized by the presence of tandem bromodomains, 
conserved domains that recognize and bind acetyl-lysine residues, and a so-called extraterminal (ET) 
domains. BRD4 represents the best-studied BET family member, which contains a domain, namely the 
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positive transcription elongation factor b (P-TEFb)-interacting domain, that binds the HIV cofactor P-TEFb 
[48]. Such bond prevents the reaction between HIV Tat and P-TEFb, which is crucial to trigger HIV 
transcription. Thus, BRD4 represents a potent HIV activation inhibitor [49]. In the light of these 
experimental observations, the  bromodomain inhibitor JQ1, a cell-permeable compound with potent anti-
cancer activity, which prevents the sequestration of P-TEFb by BRD4 hence promoting Tat-transactivation, 
has been recruited amid the strategies to disrupt HIV latency [48-50]. Li et al. demonstrated in vitro that 
the binding of JQ1 with BRD4 enhances HIV transcription [49]. It seems, indeed, that JQ1 is able to 
dissociate BRD4 from the HIV promoter thus allowing the Tat transcriptional activity [49].  Although Li et al 
claimed that JQ1 activity is TAT-dependent, a study by Boehm et al. showed that even after the removal of  
Tat from the equation, cells treated with JQ1 were able to start transcription [48]. They also demonstrated 
a role, even if of minor relevance than BRD4, of BRD2 in the activation of HIV transcription:  knockdown of 
BRD2 resulted in a robust activation of the HIV LTR, and this effect was only slightly enhanced in response 
to JQ1 [49]. 
Among LRA, disulfiram has been initially tested in HIV infected patients on stable cART to study the ability 
to induce plasma viremia since in vitro studies have demonstrated the capacity of this compound of 
inducing HIV transcription in a T cell model [51]. Despite the mechanism of action is not completely 
understood, It appears to be mediated by the depletion of the phosphatase and tensin homolog and the 
activation of protein kinase B [52]. Even though a rapid increase in the HIV viremia soon after the disulfiram 
administration, which resulted well tolerated, no effect on the size of HIV reservoir was observed in a pilot 
study by Spivak et al [53]. In a phase 2 study escalating doses of disulfiram were tested showing an increase 
in the cell-associated unspliced HIV-RNA at all doses [54]. The illustrated findings, combined with the good 
tolerability profile of this drug, suggest the possibility of use of disulfiram as LRA alone or combined with 
other molecules [55]. 
Other key molecular mechanisms involved in HIV-1 latency are sequestration of transcription 
initiation/elongation factors and blockade of the assembly of the active elongation factor, P-TEFb. The NF-
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κB pathway appears to be one of the most relevant pathways concerning HIV-1 reactivation. Protein kinase 
C agonists (PKCA) activate PKC isoforms which then phosphorylate IκB and consequently activate NF-κB. 
Several PKC agonists have been considered for purging the reservoirs of latent HIV-1[56]. First of all, 
prostratin is a unique phorbol esterthat it induces potent T cell activation signals and is not tumorigenic. 
Besides the ability of prostratin to induce T-cell activation through PKC, without tumor promoting ability, 
another unique property  is that, despite being able to reactivate latent HIV-1, it exerts an inhibitory effect 
on active HIV-1 replication through downregulation of CD4 [57]. Furthermore, bryostatin-1 has appeared to 
be an effective reversing agent. Bryostatins represent an important group of pharmaceutically promising 
substances. These compounds are produced by commensal microorganisms naturally occurring in marine 
invertebrates, mainly in bryozoans. The most frequently investigated substance is bryostatin-1, which is a 
highly oxygenated macrolide with a polyacetate backbone [58]. Its mechanism of action involves a bound to 
the diacylglycerol-binding region within the C-1 regulatory domain of PKC. Bryostatin-1 has shown to 
reactivate latent HIV-1 in vitro in monocytoid and lymphoid cell line models of latency and was 
approximately 1,000-fold more potent than prostratin [57].  However, since economic and environmental 
factors have severely limited its availability, De Cristopher et al. reported the activity of seven bryostatin-1 
analogues, dubbed “bryologs”, specifically designed to obtain molecules easier to operate with.  These 
compounds incorporate a tetrahydropyranyl B-ring formed through a versatile prins macrocyclization. They 
demonstrated that these simplified bryostatin analogues, which share the functional activity of the clinical 
candidate prostratin, are up to four orders of magnitude more potent [59]. 
Although research on latency reversing agents has collected a good amount of promising results, none of 
these compounds has provided an effective reduction in HIV reservoir size. Thus, scientists have been 
proposing combinations of different agents in order to obtain a maximal synergistic effect able to cause a 
significant contraction to the viral latent pool. First of all, it is worth mentioning the work of Reuse et al. 
who tested the combined effect of prostatin (PKC agonists) and several HADCis [60]. They demonstrated 
that the combination of prostratin plus valproic acid or suberoylanilide hydroxamic acid disrupted more 
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effectively than each compound alone the HIV-1 latency both in several latently-infected cell lines and in 
CD8+-depleted PBMCs isolated from HIV-1-infected patients receiving HAART and with undetectable viral 
load [60]. Interestingly, they also found that HADCis can degrade cytoplasmic IκBα which enhances the PKC 
agonistic activity hence boosting their combined synergism [60].  Moreover, they proved that this 
combination is effective on all the viral subtypes belonging to the HIV group M except for subtype G [60]. 
Secondly, Darcis et al. later considered the combination of PKC agonists and P-TEFb releasing compounds 
like JQ1 and the results obtained were quite promising. Initially they assessed the capability of these drugs 
of reaching a synergistic effect if administered together, so they measured the HIV-1 production and 
transcription both in U1 and in a J-Lat strain. They discovered that the combination PKC agonists plus 
iBET/hexamethylene bisacetamide strongly enhanced both production and transcription in such in 
vitro post-integration latency cellular models of T-lymphoid and myeloid lineages [61]. Furthermore, the 
combined effect of these molecules was tested ex vivo on primary cells isolated from aviremic patients on 
cART. Cultures of Isolated PBMC depleted of CD8+ T cells and cultures of resting CD4+ T cells expressed 
HIV-1 RNA levels to a degree comparable to that obtained after anti-CD3+anti-CD28 antibodies stimulation 
in presence of JQ1/Ing-B+bryostatin-1 [61]. The mechanism of action underlying the synergism was also 
partially uncovered: it seems, in fact, that on the one hand JQ1 increased bryostatin-1-induced NF-κB DNA-
binding activity and on the other hand that JQ1 and bryostatin-1 caused a higher activation of P-TEFb than 
the compounds alone [61].  Finally, the activity of PKC agonists plus JQ1 on cell surface activation markers 
was investigated. They noted that first, JQ1 did not cause the activation of resting CD4+ T cells and CD4+ 
cells - analyzed from the CD8-depleted pool -and second, that the combination of PKC agonists and JQ1 led 
to the activation of cell markers such as CD69 and HLA-DR and to a downregulation of CD38 and CD25 
compared with the PKC agonists effect alone. Consequently, it is reasonable to say that the combination 
causes a minor T cell activation which is fundamental towards a clinical prospective, since compounds 
which trigger a non-specific or robust immune activation are inappropriate for in vivo applications. 
Moreover, the combination PKC agonist plus JQ1 led to the downregulation of CD4 receptor, which could 
be beneficial for the blockade of de novo HIV infections [61].   
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Toll–like receptor molecules (TLRs) are a class of antigen-presenting cells trans membrane proteins located 
on the cell surface or on the membrane of endocytic vesicles and other intra-cellular organelles. They are 
capable of recognizing a wide range infectious disease pathogen-associated molecular patterns (PAMP). 
TLRs are divided in two main groups: i) surface TLRs such as TLR-1, TLR-2, TLR-4, TLR-5, TLR-6, and TLR-11 
mainly capable of identifying microbial membrane components such as lipids, lipoproteins, and flagella and 
ii) TLR-3, TLR-7, TLR-8, and TLR-9 which are expressed in intracellular vesicles of the endoplasmic reticulum, 
endosomes, and lysosomes and recognize both viral and microbial nucleic acids [62]. TLRs activation by 
their ligands implicates the expression of the adaptor protein My88 and the nuclear factor NF-κB. In 
particular TLR-7 is well known to be involved in the recognition of single-stranded RNA fragments located in 
endosomes and its activation is a common feature of viral infections.(59). In fact, TLR-7 agonists have 
already been studied as potential HIV inhibition targets [63, 64]. Moreover, as already mentioned by Sloan 
at Croi 2015 and confirmed by Tsai et al., TLR-7 agonists also have (especially GS-9620) a high potential as 
HIV inducers in HIV siero-converted patients on HAART. Indeed, Tsai found that GS-9620 can induce 
extracellular RNA ex vivo on the PBMCs of 27 out 36 of the patients tested, independently of their basal 
HIV-RNA levels and is capable of stimulating the production of INF-α, which plays a key role in HIV induction 
[65]. Besides, it was discovered that GS-9620 can upregulate the expression of CD69 and consequently 
activate CD4 and CD8 both in the presence and absence of HIV antigens, even though in the first case the 
level is much higher [65]. Furthermore, it was noticed that the molecule was able to enhance the CD8 
cytolytic effect and that this same effect is strictly connected with the activation of IFN-α (62). Finally, Tsai 
et al. proved that immune effector cells, like monocyte and dendritic cells, due to the upregulation of CD80 
as well as CD69 consequent to the exposure to GS-9620, more effectively recognize and kill HIV-infected 
target cells in the presence of effector-competent bNAbs [65]. Also, maraviroc have been investigated 
among LRAs, alone or combined with PKC-agonists, in fact this CCR5 antagonist can activate NF-κB and, 
subsequently, induce latent HIV-1-transcription in resting CD4+ T-cells from HIV-1-infected individuals on 
suppressive antiretroviral therapy [66, 67].  
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3.2 The “kill” 
As to the “kill” part of the strategy, various studies have shown that neither the virus nor the immune 
system is effective in clearing infected cells after latency reversal; in one in vitro model, infected resting 
CD4+ T cells survived despite viral cytopathic effects [68]. Further, because most of the virus has mutated 
to escape immune responses, escape variants dominate in the latent reservoir of people with chronic 
infection [69]. Unfortunately, therapeutic vaccines to augment immune responses have resulted in 
transient expansion of T cells that do not recognize escaped HIV epitopes [70]. Several trials of vaccines to 
increase the strength of HIV-specific immune response have been completed in the last years, and overall 
results show that vaccination is safe and immunogenic, but useless in eliminating HIV. Moreover, a great 
number of shock-and-kill studies have combined LRAs with approaches such as therapeutic vaccines, 
interferon, and broadly neutralizing antibodies to enhance immune response. In one study of 20 individuals 
on antiretroviral therapy who had a viral load below 50 HIV RNA copies/mL for more than 3 years, the 
combination of the HDACi romidepsin and the HIV peptide vaccine resulted in no change in integrated DNA 
or infectious virus. If on one side a statistically significant decline in total HIV DNA was observed on the 
other the effect was clinically insignificant, because viral rebound after cessation of antiretroviral therapy 
was always observed within 2 to 4 weeks [71]. In a recent study, the use of a different HIV vaccine in com-
bination with romidepsin was associated with viral rebound within 4 weeks of interruption of antiretroviral 
drugs in 8 participants; 5 other articipants exhibited sustained lower level viremia during the interruption 
[72]. Lim et al. treated SIV-infected rhesus macaques on antiretroviral therapy with up to 19 doses of the 
TLR-7 agonists GS-986 or GS-9620. By the third dose, all macaques experienced a transient SIV plasma 
viremia within 48 hours after dosing. The dose regimen was also associated with activation of lymphocytes 
(T, NK, and B cells) and a reduction in SIV DNA in cells from the peripheral blood, lymph nodes, and 
gastrointestinal tract. When antiretroviral therapy ceased, 2 out of 13 treated macaques did not show 
rebound of virus and remained virus-free and disease-free for more than 2 years [73]. In the same study, 
the depletion of CD8 cells did not induced a rebound of the SIV RNA in the 2 aviremic macaques. Moreover, 
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the transfer of cells from aviremic animals to uninfected ones did not produce de novo infection. These 
findings suggested a possible role of TLR-7 agonist in reducing the viral reservoir in a subset of macaque 
infected with SIV. 
In recent years the possible use of compounds employed in cancer therapy, with the ability of interfering 
with apoptotic pathways, was postulated for potential HIV curative intervention (Table 3) [29]. Among 
these bcl-2 antagonists, venetoclax, which causes selective killing of HIV-infected cells resulting in a 
decreased of HIV DNA-containing cells, has been tested in vitro as a potential strategy to reduce reservoir 
size [74]. Another class of compounds is the phosphoinositide 3-kinase (PI3K)/AKT inhibitors, i.e. elefosine, 
perifosine and milefosine, which have the ability of reducing the HIV-1 production from long-living virus-
infected macrophages. The potential application of these compounds could be the block of the 
establishment of the HIV reservoir by interfering with the cytoprotective effect of HIV-1 infection, which 
extends the lifespan of infected macrophages by the PI3k/AKT pathway interference [75]. Another 
approach potentially able to revert HIV latency could be the block of Baculoviral IAP Repeat Containing 2 
(BIRC2) by small molecules named Smac mimetics. In fact, ubiquitin ligase BIRC2 which is a repressor of the 
NF-κB pathway, is a potent negative regulator of LTR-dependent HIV-1 transcription  [29]. Successful in 
vitro strategies have combined the HDACi panobinostat with Smac mimetics with a synergistic effect in the 
reversal of HIV latency [76]. Finally, retinoic acid inducible gene 1 (RIG-1) inducers, i.e. acitrecin, which have 
been tested as potential compounds able to revert and selectively kill the HIV latently infected cells, alone 
or combined with vorinostat, failed in reverting latently HIV infected cells and in selectively killing of HIV 
positive cells [77]. 
 
4.0 Immune therapy 
A detailed understanding of how the host immune system shapes the size and distribution of the viral 
reservoir should lead to the development of a new generation of immune-based therapeutics, which might 
eventually contribute to a curative intervention [78]. CTLA-4+/ programmed death-1(PD1)- CD4+ T cells 
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with features of T regulatory cells are critical for viral persistence in lymphoid tissues and should be 
targeted as part of HIV cure strategies, as well as CD8 depletion in SIV-infected macaques on ART , 
suggesting that CD8 cells play an ongoing role in viral control even during suppressive ART [79, 80]. Finally, 
recent studies using IL-21 and interferon alpha have modulated viral rebound and improved immune 
control in infected animals after ART interruption [81]. 
Immunosuppressive pathways or immune checkpoints are known to be inhibitory receptors expressed on 
the surface of several immune cell subsets and have the function of maintaining self-tolerance and 
controlling the physiological course of immune response in peripheral tissues, in order to minimize 
collateral tissue damage [82]. Such Immunosuppressive pathways lead to 'exhausted' T cells, which show 
inferior effector function, sustained expression of immune checkpoint molecules such as PD1, poor recall 
responses and an uncommon transcriptional state [83]. Many pathogens and malignancies use these 
pathways as immune escape strategy, such as HIV. Indeed, several clinical trials involving checkpoint 
inhibitors as pharmacological targets have been starting on cancer patients [82]. PD1, Cytotoxic T-
Lymphocyte Antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) and 
Lymphocyte-activation gene 3 (LAG-3) are the most commonly upregulated proteins, expressed both on 
CD4+ and CD8+ T cells. Their expression is majorly observed in HIV-untreated infection, nevertheless even 
patients on cART, albeit lower, present an elevated level of immune checkpoint proteins in comparison 
with controls [84]. It was proved that the administration of PD-1 antibody to SIV-infected macaques 
resulted in a rapid expansion of CD8+ T cells with a reduction in the interferon signaling pathways and 
reduction in intestinal microbial translocation [85, 86]. Moreover, a single study in a patient with metastatic 
melanoma and HIV treated with anti-CTLA4 (ipilimumab) and anti-PD1 (nivolumab) antibodies showed an 
increase in cell-associated HIV-1 RNA [87, 88]. So far, the only trial assessing an immune checkpoint blocker 
in individuals with HIV infection without malignancy was a phase II dose-escalation study with an anti-PDL1 
antibody (BMS-936559), which was prematurely interrupted for concomitant retinal toxicity in a 
simultaneous study in macaques. Moreover, one patient, among the six tested, developed hypophysitis 
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after several months from the discontinuation of the compound, thus raising concern about the safety of 
this class of compounds [89]. Furthermore, a recent study released on June 2018 by Porichis et al describes 
the relationship between restored CD4+ T cells and NK cells [90]. Their ex vivo analysis shows that the 
inhibition of two main immunosuppressive pathways contributing to HIV-specific T cell exhaustion, PD-1 
and IL-10, increases NK function through reinvigorated HIV-specific CD4 T cell help both in patients on cART 
or untreated. These results suggest that reversion of CD4 T cell exhaustion in HIV infection can provide a 
more efficient viral control by boosting the innate immunity response. This model considers cytokines as 
important mediators of CD4 T cell help to NK cells; as a matter of fact, IL-2 secreted by CD4+ T cells can 
stimulate NK and elicit secretion of cytokines such as IL-12 by APCs, which in turn is a potent activator of NK 
cell function. Their results suggested that the reversal of adaptive immunity exhaustion can improve the 
innate immune response and immune checkpoint modulation could be used as adjuvant therapy in HIV 
infection [90]. 
It has been shown the importance of other interleukins, i.e. IL-15, in enhancing the survival and also the 
effector function of HIV specific CD8+ specific lymphocytes which are fundamental for the control of HIV 
replication [91]. Recent data have shown how the use of IL-15 superagonist ALT-803 is able to invert the 
trafficking of SIV specific CD8+ cells from peripheral blood to lymph nodes, and in particular inside B cells 
follicles [92]. Moreover, in rhesus macaques IL-15 superagonist ALT-803 has the ability to increase both NK 
cells and  CD8 + cells with an im act in the reduction of SIV viremia, albeit transiently [93]. 
5.0 Non pharmacological strategies 
5.1 Broadly neutralizing antibodies 
Along with the discovery of numerous HIV-1–specific broadly neutralizing antibodies (bNAbs)[94-96], it has 
become evident that viral co-evolution is likely required to induce potent bNAbs during the natural course 
of infection by mature B lymphocytes [97, 98]. One of the bNAbs’ possible mechanisms of action  against 
HIV infected cells may be the increase of the host immunity or FcγR-dependent mechanism by forming an 
immune complex for eliciting CD8+ T cell responses [99, 100]. Previous studies have shown that bNAbs 
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administered at the time of ART discontinuation can provide direct antiviral effects, but whether bNAbs can 
effectively target the viral reservoir during ART suppression remains to be determined. Recent work has 
shown that bNAbs can clear cell-free virus and infected cells that express HIV [101]. Proviral DNA was 
reduced in macaques treated with these antibodies [102, 103]. However, the extent of the antibodies 
ability to clear latently infected cells is not well understood. The first bNAbs studied in the VRC01 phase I 
study showed that a single infusion was associated with various degrees of viral suppression in viremic 
patients ranging from a sustained suppression of HIV replication to no inhibition of viral replication [104]. 
The emergence of resistant virus strains has arisen as the major problem with this therapeutic approach 
leading to the recrudescence of viral replication in plasma after a median time of about five weeks after 
cART interruption, albeit therapeutic levels of VRC01 were detected[105]. Similar findings have been 
observed in a analogous investigation by using 3BNC117 bNAbs [106]. The next step in the development of 
such types of bNAbs has been the increase of the potency of the autoantibodies combined with a broader 
coverage of the envelope escaping variants. Engineering strategy has led to the extension of the half-life of 
this bNAbs by modifying the Fc region causing a block of the endosomal degradation. Moreover, this new 
technology has permitted the co-formulation of different bNabs in a single compound accounting for a 
greater breadth of coverage when compared to first generation bNAbs [107, 108]. in vitro and ex-vivo data 
have shown how bispecific antibodies directed against GP-120 HIV surface protein, using either the scFv 
B12 or VRC01, are able to inhibits HIV replication not only in PBMCs but also in macrophages co-cultured 
with autologous CD8+ T-cells. The combination of these antibody constructs with latency reversible agents 
could potentially be an option to taking into account as future approach for HIV-cure since has shown an 
efficient killing of GP-120 expressing cells and the inhibition of HIV replication both in PBMCs as well as in 
macrophages [109]. An in vivo study, in humanized mice, has shown that an injection of a bispecific bNAns, 
BiIA-SG, can confer protection against the infection by several different HIV strains when administered 
before the challenges with live HIV-1 viruses. Moreover, BiIA-SG delayed HIV infection when compared to 
cART. A single injection of adeno-associated virus–transferred BiIA-SG gene resulted in prolonged in vivo 
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expression of BiIA-SG leading to HIV replication control and subsequently to the elimination of infected 
cells in humanized mice [110]. 
Several human studies are planned in order to evaluate the effects of passively infused antibodies on the 
HIV reservoir. Immune checkpoint blockers such as anti-programmed cell death-1 antibody could improve 
function and persistence of effector T cells [78]. Targeted cytotoxic therapy using immunotoxin is another 
potential path [111]. One of the possible bNAbs routs of administration  assessed was the delivery by an 
adeno associated virus in rhesus monkeys with the achievement of a sustained viral remission by using two 
different bNAbs [112]. Despite the maintenance of viral replication control of a period covering 
approximately 20 months, viral replication rebounded in rhesus monkeys showing how this kind of 
intervention could potentially be accounted  for a “functional cure” approach but not for strategies aiming 
the eradication of the viral reservoir [113]. ConverselyBorducchi et al. have assessed the impact of the V3 
glycan-dependent bNAb PGT121 combined with the TLR-7 agonist GS-9620 in ART-suppressed SHIV-
infected rhesus monkeys. The Authors showed that in rhesus monkeys infected with SHIV, that initiated 
cART during acute infection, a combination of PGT121 and GS-9620 during cART suppression substantially 
delayed and controlled viral rebound following cART discontinuation. Such data suggest that bNAb 
administration together with innate immune stimulation during effective cART may effectively target the 
viral reservoir [114] . Two trials are now planned. The first one will be a controlled test of a conserved gag-
pol peptide-stimulated dendritic cell vaccine in 28 acutely infected participants (Fiebig stage I–III) from the 
RV254 clade AE cohort in Thailand. In this trial an analytical treatment interruption (ATI) will determine the 
effect of the vaccine on viral rebound and control [115]. The other one will test passive administration of a 
combination of two bNAbs (PGT121 + PGDM1400) in 30 participants from the clade C FRESH cohort of 
early-treated individuals (Fiebig stage I–III) in South Africa in a placebo controlled, randomised study [116]. 
One of the last drugs developed for HIV treatment is an anti-CD4 (IgG4 humanized) monoclonal antibody, 
ibalizumab [117]. Ibalizumab was developed initially for HIV prevention strategies and actually is licensed 
for the treatment of drug resistance viruses as a component of salvage strategies [118]. Although 
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ibalizumab showed in a phase 3 study to be effective against multi-drug resistance viruses, the 
development of escape mutants has been observed [119].  
Another humanized monoclonal antibody is PRO 140, which binds to CCR5 inhibiting R5 tropic viruses 
without any role in blocking CXCR4-using viruses [120]. This compound was tested in a phase II study 
administered intravenously in which a single intravenous infusion has been demonstrated to have potent, 
long-lasting antiretroviral activity with a favourable safety profile [121]. Nowadays, there are ongoing phase 
IIb and III trials in patients with virologic failure and as monotherapy maintenance strategy in patients with 
viral suppression [122].  
5.2 Gene and cell therapy 
As it has previously mentioned, the anecdotal case of the “Berlin patient” highlights the possibility of HIV 
eradication by allopoietic bone marrow cells transplantation with implanted cells intrinsically resistant to 
HIV infection [11]. Nevertheless, this case was not further reproduced; a recent work by Colonna et al. in 
cART-suppressed non-human primates infected by SIV showed how allopoietic hematopoietic cell 
transplantation is insufficient for HIV eradication despite high-level donor chimerism and graft versus host 
disease due to the persistence of HIV in multiple sites including the brain [123]. Nowadays, several strategies 
based on gene and cell therapy have been tested in order to evaluate HIV cure approaches from in vitro 
studies to clinical trial [124]. These include engineering HIV-specific immunity in T-cells, gene editing 
approaches to render all blood cells in the body HIV-resistant starting from the proof of concept of the 
“Berlin patient”, and a combination of both these strategies. As for pharmacological intervention, it is 
unlikely that a single intervention could lead to complete HIV eradication. Conversely, a combination of 
multiple intervention based on cell and gene therapy are more likely to give some results. 
6.0 Conclusion 
In this review, we assessed several pharmacological strategies, which have been tested as HIV curative 
interventions. As things stand, no one of these approaches have been demonstrated, in vivo, capable of 
leading to viral eradication despite strong in vitro and ex vivo data, i.e. shock and kill. A deep understanding 
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of HIV viral latency mechanisms combined with a better knowledge and characterization of HIV reservoir 
are crucial for the development of future pharmacological strategies. 
7.0 Expert opinion 
Despite an incredible effort has been made to decode and interpret the mechanisms underlying HIV viral 
latency and the establishment and perpetuation of viral reservoir, no effective strategy has been 
demonstrated capable to completely eradicate HIV infection.  
One of the potential targets of pharmacological curative research is primary HIV infection. In fact, it 
represents a great opportunity for potential curative intervention due to the possibility of reducing the size 
of viral reservoir with very early pharmacological treatment. It is now clear that cART alone, even if started 
in the first phase of infection, i.e. Fiebig I, is not able to eradicate the virus, but only in few cases it 
potentially led to a post-treatment control of viral replication after structured treatment interruption. 
Future studies need to focus on the combination of multiple interventions both pharmacological, i.e. cART, 
and immunological, i.e. vaccines and bNAbs, with the aim to hit different targets of the viral replicative 
cycle and latency mechanisms.  
In regards to “shock and kill”, which is the most widely investigated among curative intervention strategies, 
the great challenge is the possibility to apply in vitro and ex vivo discovery firstly to animal model and 
secondly to clinical practice. This gap is unfortunately not negligible and the great majority of research in 
the field had the limit of the difficult applicability in vivo. In fact, when we face up with new interventions 
we have to take into account important ethical, social and behavioural research questions in parallel [125, 
126]. The great majority of these strategies poses significant health risks with realistically modest benefit to 
trial participants. Moreover, the proof of concept of HIV cure and remission is the structured treatment 
interruption. If on the one hand we could limit the potential problems related to viral rebound for the 
subject with a close monitor and a rapid resumption of cART, on the other hand we pose the subject in a 
condition of medicalization that would not be necessary if the patient was still on cART. Furthermore, the 
effect of a potential resettlement of the viral reservoir during cART interruption is unclear [127].  
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Eventually, immunological approaches alone are unlikely to be effective in HIV cure. Regarding immune 
therapy, check-points inhibitors seem to be promising. Unfortunately, toxicity concern has arisen from the 
first trial on HIV-positive patients without cancer, thus delaying it involvement as therapeutic strategy in 
HIV positive individuals. Options accounting for the use of bNAbs may have the most clinical applicable with 
good safety data in vivo. One limitation of this therapeutic intervention is the route of administration and 
the appearance of viral resistant strains. bNAbs could likely be an option for cART-free remission 
interventions, whether they could not be effective as curative action. 
Since every single strategy alone have failed to reach the ambitious goal of curing HIV, the next step will be 
the development of multiple steps and target interventions, thus considering the combination of 
pharmacological and immune agents, i.e. LRA, inflammatory pathway blockage, therapeutic vaccines and 
other interventions. The objective is at least to induce a cART free remission and whether possible a 
complete viral eradication.  
After the description of the VISCONTI cohort [25] and the explanation of the “shock and kill” [29] line of 
research, the field of the HIV cure has been dramatically developed. Together with excellent data and 
sporadic pitfalls, alternate waves of hope and discomfort are still present in the most prominent research 
initiatives. 
The “Berlin patient” remains a great success, yet anecdotal. In parallel, the “Mississippi” and “Milan” babies 
and the “Boston” patients [18, 27, 128] revealed that the reality is harsher that scientific promises, 
although well built. As clinicians and researchers who care for HIV-positive patients, we do not know if 
these strategies will ever be feasible, but we surely realize that it is worth trying to find a solution. In the 
next 5 years, a series of issues need to be elucidated, as a substantial step before adding them into the 
clinical practice, such as (i) identifying biomarkers that do rationally have an impact on the inflammation 
profile and (ii) ways of measuring the viral reservoir. This couple of activities aim at assessing both sides of 
the same medal, i.e. the reaction by the immune system and the ways in which HIV replicates or hides. The 
challenge will be to measure them in the most effective and accurate way. 
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Other than these obstacles, some approaches look in a better shape than others and will be more 
extensively developed in the next 5 years. These tools will include (i) several check-point inhibitors 
developed in cancer research, the most promising being those which block the axis PD-1/PDL-1 and CTLA-4 
and (ii) multiple broadly neutralizing antibodies, some of which already concluded clinical trials. 
It is not going to be a déjà vu and the best way to use these new resources will be as multi-target 
combination therapies, which, as expected, will need to take into consideration not only the power of the 
combination but the complex burden of side effects. 
8. Article highlights 
• In the early phases of HIV infection the establishment of a reservoir composed by quiescent and 
long lasting cells represents the major obstacle to HIV eradication. 
• Intervention strategies in acute HIV infection could lead to a significant reduction in the reservoir’s 
size but inexorably HIV-RNA rebounds in plasma after cART interruption even if the reservoir result 
unquantifiable. 
• Shock and kill strategies have the aim of revert the latency of quiescent cells composing the HIV 
reservoir and subsequently kill the same cell. Several models have demonstrated how this kind of 
intervention can be effective in vitro and in animal model, but at the moment no strategy has been 
demonstrated to be effective in reducing the reservoir size in clinical studies. 
• Immunological strategies accounting for the use of check-point inhibitors developed in cancer 
research seems to be promising. To date, the major concern regards the safety profile for this class 
of compounds. 
• Broadly neutralizing antibodies represent not only an option among strategies for long term control 
of HIV viremia and HIV prevention but they could be also part of combined strategies for targeting 
HIV reservoir as a part of kill interventions. 
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• Since every single strategy has failed in HIV eradication, the future interventions will have to focus 
on multitarget combination therapies. 
 
 
Figure legend 
Figure 1. Pharmacological classes of drugs with specific compounds, stage of development and potential 
application in the current strategies of HIV eradication.  
†Clinical trial 
 χAnimal model 
*In vitro/ex vivo 
List of abbreviations: HDACi (Histone Deacetylase Inhibitors), TLR7 (TOOL-LIKE RECEPTOR 7 AGONISTS), BETi 
(BROMODOMAIN EXTRATERMINAL INHIBITORS), PD-1 (Programmed cell Death protein-1), Bcl-2 (B-cell 
lymphoma 2), PI3K/AKT (Phosphatidylinositol-4,5-bisphosphate 3-kinase/Protein kinase B), Smax (Second 
Mitochondria-derived Activator of Caspases), XIAP (X-linked inhibitor of apoptosis protein), RIG-1 (retinoic 
acid-inducible gene I). 
Table legend 
Table 1: Class of drug tested as a part of shock strategies, rationale and mechanism of action and relative 
stage of development.  
List of abbreviations: HDACi (Histone Deacetylase Inhibitors), PKCA (PROTEIN KINASE AGONISTS), NF-kb 
(nuclear factor kappa-light-chain-enhancer of activated B cells), TLR7 (TOOL-LIKE RECEPTOR 7 AGONISTS), 
BETi (BROMODOMAIN EXTRATERMINAL INHIBITORS), p-TEFb (positive transcription elongation), 
Bromodomain-containing protein 4 (BRD4), PKB (Protein kinase B), AKT (Protein kinase B). 
Table 2: List of histone deacetylase inhibitors, their use outside HIV infection and potential effect as latency 
reverting agents.  
List of abbreviations: HDACi (Histone deacetylase inhibitors), HIV-1 CA-US-RNA (Human Immunodeficiency 
Virus-1 Cell Associated-Unspliced-RNA), FDA (Food and Drug Administration).  
Table 3: Class of drug tested as a part of kill strategies, rationale and mechanism of action and relative stage 
of development. 
List of abbreviations: Bcl-2 (B-cell lymphoma 2), PI3K/AKT (Phosphatidylinositol-4,5-bisphosphate 3-
kinase/Protein kinase B), FOXO1 (Forkhead box protein O1), Smax (Second Mitochondria-derived Activator 
of Caspases), XIAP (X-linked inhibitor of apoptosis protein), RIG-1 (retinoic acid-inducible gene I), DexD/H 
(DexD/Helicase) 
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Pharmacological 
family 
Mode of action Agents tested  Phase of 
development 
HDACi Inhibition of histone 
deacetylationchromatin 
relaxiontranscription induction 
[129, 133]  
- Valproic acid [34, 
130] 
 
 
-  Vorinostat [30]  
- Panobinostat 
[132] 
- Romidepsin [71]  
- Proof-of-
concept and 
multicenter 
crossover 
study 
 
- Phase I-II 
 
- Phase I-II 
 
 
- Phase Ib/IIa 
PKCA Activation of PKC isoforms  iκB 
phosphorylation  NF-κB 
activation  P-TEFb elongation 
factor activation [55] 
- Prostratin [58]  
- Bryostatin-1 [131]  
- ex vivo 
 
- in vivo 
TLR7 AGONISTS Recognition of single-stranded 
RNAs  expression of My-88  
cytokine production [63]  
- Vesatolimod (GS-9620) 
[64.65.73]  
- animal model 
- Ongoing Phase I trial 
DISULFIRAM  Not clear involvement in PTEN 
depletion  phosphorylation of 
PKB  Akt pathway activation 
[51]  
- Disulfiram [53, 54]  - Phase II 
BETi Inhibition of BRD4-P-TEFb binding 
 P-TEFb-Tat binding  
transcription [49]  
- JQ1 [48, 131]  - in vivo 
 
Table 1: Class of drug tested as a part of shock strategies, rationale and mechanism of action and relative 
stage of development.  
List of abbreviations: HDACi (Histone Deacetylase Inhibitors), PKCA (PROTEIN KINASE AGONISTS), NF-kb 
(nuclear factor kappa-light-chain-enhancer of activated B cells), TLR7 (TOOL-LIKE RECEPTOR 7 AGONISTS), 
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BETi (BROMODOMAIN EXTRATERMINAL INHIBITORS), p-TEFb (positive transcription elongation), 
Bromodomain-containing protein 4 (BRD4), PKB (Protein kinase B), AKT (Protein kinase B). 
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HDACi OTHER USES Increase of 
HIV-1 CA-US-
RNA 
Increase of 
plasmatic 
HIV-1 RNA 
HIV-1 DNA 
reduction 
VALPROIC ACID 
(31) 
FDA-approved against seizures, 
migraine, bipolarism  
YES NO NO 
VORINOSTAT (34)  FDA-approved against cutaneous T-
cell Lymphoma (122) 
YES NO NO 
PANOBINOSTAT 
(121) 
FDA-approved against Multiple 
Mieloma (122) 
YES YES NO 
ROMIDESPIN(42) FDA-approved against cutaneous T-
cell Lymphoma and peripheral T-
cell Lymphoma(122)  
YES YES NO 
 
Table 2: List of histone deacetylase inhibitors, their use outside HIV infection and potential effect as latency 
reverting agents.  
List of abbreviations: HDACi (Histone deacetylase inhibitors), HIV-1 CA-US-RNA (Human Immunodeficiency 
Virus-1 Cell Associated-Unspliced-RNA), FDA (Food and Drug Administration).  
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Pharmacological 
family 
Mode of action Stage of development 
Bcl-2 antagonist  Mimicking of BH3 with higher bindgin 
affinity for Bcl-2 binding  blockade of anti-
apoptotic effect [29]  
 venetoclax and navitoclax (in 
vitro) [74, 132, 134]  
PI3K/Akt inhibitors Inhibition of Akt activation  activation of 
FOXO-1 transcrition factor  expression of 
pro-apoptotic molecules [29]  
elefosine, perifosine a            
milefosine (in vitro) [75]  
Smac mimetics/XIAP 
inhibitors 
Competition for the binding with XIAP  
activation of cascape 3, 7 and 9 [29]  
Birinapant, AEG40730 –SM- (in 
vitro) [136] 
 GDC-0152, embelin (in vitro) 
[137] 
RIG-1 inducers Rig-I is a DexD/H box RNA helicase that 
sense viral Rna  apoptosis induction [29]  
Retinoi acid, retinoic acid-like, 
Acicretin (in vitro) [135] 
 
Table 3: Class of drug tested as a part of kill strategies, rationale and mechanism of action and relative stage 
of development. 
List of abbreviations: Bcl-2 (B-cell lymphoma 2), PI3K/AKT (Phosphatidylinositol-4,5-bisphosphate 3-
kinase/Protein kinase B), FOXO1 (Forkhead box protein O1), Smax (Second Mitochondria-derived Activator 
of Caspases), XIAP (X-linked inhibitor of apoptosis protein), RIG-1 (retinoic acid-inducible gene I), DexD/H 
(DexD/Helicase) 
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Figure 1. Pharmacological classes of drugs with specific compounds, stage of development and potential 
application in the current strategies of HIV eradication.  
†Clinical trial 
 χAnimal model 
*In vitro/ex vivo 
List of abbreviations: HDACi (Histone Deacetylase Inhibitors), TLR7 (TOOL-LIKE RECEPTOR 7 AGONISTS), BETi 
(BROMODOMAIN EXTRATERMINAL INHIBITORS), PD-1 (Programmed cell Death protein-1), Bcl-2 (B-cell 
lymphoma 2), PI3K/AKT (Phosphatidylinositol-4,5-bisphosphate 3-kinase/Protein kinase B), Smax (Second 
Mitochondria-derived Activator of Caspases), XIAP (X-linked inhibitor of apoptosis protein), RIG-1 (retinoic 
acid-inducible gene I). 
 
 
